- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06297213
R-2487 in Patients With Sjogren's Syndrome (SjD) (R-2487-SjD-01)
A Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients With Sjogren's Syndrome (SjD)
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Sjogren's Syndrome.
Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Sjogren's Syndrome. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Christian Freguia, PhD
- Telefoonnummer: 2159231818
- E-mail: cfreguia@risetherapeutics.com
Studie Contact Back-up
- Naam: Janet Stephens, PhD
- Telefoonnummer: 650-417-8556
- E-mail: jstephens@risetherapeutics.com
Studie Locaties
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21224
- The Johns Hopkins Jerome L. Greene Sjögren's Syndrome Center Johns Hopkins University - Rheumatology Department
-
Contact:
- Priya Patel
- Telefoonnummer: 410-550-9821
- E-mail: ppate132@jh.edu
-
Hoofdonderzoeker:
- Alan Baer, MD
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- University of Michigan - Michigan Medicine
-
Contact:
- April Lucas
- Telefoonnummer: 734-615-9865
- E-mail: aplucas@med.umich.edu
-
Hoofdonderzoeker:
- Sara McCoy, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Diagnosis of SS according to American-European Consensus Group Criteria
- Able to provide informed consent
- Subjects receiving prednisone (10 mg or less/day) must be on a stable dose for more than 2 weeks
- All male and female subjects who are biologically capable of having children must agree to use medically acceptable method of birth control for the duration of the study. All female subjects who are biologically capable of having children must have a negative pregnancy test result before administration of investigational product.
- The use of probiotics prior to study enrollment is accepted; however, during the course of the study, the use of probiotics is forbidden.
Exclusion Criteria:
- No known active overlapping or associated other autoimmune disease
- Prior allogenic or autologous bone marrow or organ transplantation
- Subjects with prior irradiation to the head and neck, including radioactive iodine treatment for hyperthyroidism
- Subjects who have a present malignancy or previous malignancy within the last 5 years prior to screening (except documented history of cured non-metastatic squamous or basal cell skin carcinoma or cervical carcinoma in situ). Subjects who had a screening procedure that is suspicious for malignancy, and in whom the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory or other diagnostic evaluations.
- Subjects with positive results for human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
- Subjects with active viral, bacterial, or fungal infection, or history of severe opportunistic infection within the preceding 3 months, or COVID-19 infection in the past 3 months
- Subjects with evidence of active or latent tuberculosis
- Active infection of the salivary or lacrimal glands
- Prior immunotherapy, biologics, or investigational therapy must have completed at least 5 half-lives or 30 days, whichever is longer, prior to the first dose of R-2487 DP
- Pregnant or breastfeeding women
- Current clinical findings of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, endocrine, neurological, or cerebral disease with laboratory values as following:
Hemoglobin level < 9.0 g/dL
Absolute white blood cell (WBC) count of <3.0×109/L (<3000/mm3), or absolute neutrophil count of <1.2×109/L (<1200/mm3), or absolute lymphocyte count of <0.8×109/L (<800/mm3).
Thrombocytopenia, defined by platelet count <100×109/L (<100,000/mm3)
Chronic kidney disease defined as Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2, based on the age appropriate calculation.
Proteinuria ≥3+.
Total bilirubin (T-bili), aspartate aminotransferase (AST), alanine aminotransferase (ALT) more than 1.5 times upper limit of normal (ULN).
Previously diagnosed hepatic cirrhosis (Child Pugh A or higher) or previously diagnosed significant liver fibrosis (> F3)
- Any form of vaccination in the last 30 days, to include but not limited to influenza, COVID, shingles, tetanus, hepatitis, pneumonia, HPV, DPT, MMR, and polio.
- Subjects should not receive any of the following medications:
Rituximab or belimumab within 6 months prior to Day 1 Abatacept within 3 months prior to Day 1 Infliximab, Adalimumab, Certolizumab, Tocilizumab, Cyclosporine, or Mycophenolate mofetil within 2 months prior to Day 1 Etanercept, Anakinra, Immunoglobulin, or blood products within 28 days prior to Day 1
- Prior immunotherapy, including systemic corticosteroids, such prednisone, biologics, Janus kinase (JAK) inhibitors (such as tofacitinib, or upadacitinib), ozanimod, or investigational therapy must have completed at least 5 half-lives or 30 days, whichever is longer, prior to Day 0, unless otherwise specified. In the case of cell-depleting therapies, such as B or T cell depletion, cell counts must have recovered to acceptable or baseline levels (use of licensed agents for indications not listed in the package insert is permitted).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: Open Label
Probiotic |
R-2487 DP
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence and severity of adverse events and their relationship to R-2487 (probiotic) administration
Tijdsspanne: Baseline through Week 4
|
To assess the number of participants with treatment-related adverse events after taking R-2487 (probiotic) |
Baseline through Week 4
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in disease activity through Clinical European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ClinESSDAI)
Tijdsspanne: Baseline through Week 4
|
Change from Baseline in Disease Activity Score at Week 4 to assess the disease severity of Sjogren's syndrome using data without laboratory results |
Baseline through Week 4
|
|
Change in Patient reported general health questionnaire Short Form Health Survey-36(SF-36)
Tijdsspanne: Baseline through week 4
|
Baseline Short Form Health Survey-36 (SF-36) Score over time. The Baseline Short Form Health Survey is the numerical sum of 36 patient reported outcome parameters of quality of life. The higher the score the more favorable the reflection of the quality of life. |
Baseline through week 4
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Musculoskeletale aandoeningen
- Mondziekten
- Stomatognatische ziekten
- Artritis
- Gewrichtsziekten
- Reumatische aandoeningen
- Bindweefselziekten
- Auto-immuunziekten
- Ziekten van het immuunsysteem
- Oogziekten
- Artritis, reumatoïde
- Xerostomie
- Speekselklierziekten
- Droge-ogen-syndroom
- Ziekten van het traanapparaat
- Huid- en bindweefselaandoeningen
- Syndroom van Sjogren
- Voedingssupplementen
- Voedsel
- Dieet, voedsel en voeding
- Fysiologische fenomenen
- Eten en dranken
- Probiotica
Andere studie-ID-nummers
- R-2487-SjD-01
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .